| 0 | 💬 0 |
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.
(linkinghub.elsevier.com)
|
Lancet Infectious Diseases 2026-06-30 | #vaccination #immunogenicity #hpv #clinical trial #cervical cancer |